Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series

Michelle Phung; Jorge R Georgakopoulos; Arvin Ighani; Lyne Giroux; Jensen Yeung

doi:10.1016/j.jdcr.2017.11.006

Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series

JAAD Case Rep. 2018 Mar 31;4(4):310-313. doi: 10.1016/j.jdcr.2017.11.006. eCollection 2018 May.

Authors

Michelle Phung¹, Jorge R Georgakopoulos², Arvin Ighani³, Lyne Giroux⁴, Jensen Yeung^{5

6}

Affiliations

¹ Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.
² Schulich School of Medicine and Dentistry, Western University, London, Canada.
³ Faculty of Medicine, University of Toronto, Toronto, Canada.
⁴ Department of Dermatology, The Northern Ontario School of Medicine, Sudbury, Canada.
⁵ Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, Canada.
⁶ Probity Medical Research, Waterloo, Canada.

No abstract available

Keywords: AE, adverse event; PASI, Psoriasis Area and Severity Index; PASI-75, 75% reduction from baseline PASI score; PGA, Physician Global Assessment; dose escalation; dose optimization; psoriasis; secukinumab.

Publication types

Case Reports